Cancer · 1971 · 33 citations · 7 references
Life SciencesImmunologyOncologyCancer ImmunologyHypersensitivityTumor ImmunologyDelayed-type HypersensitivityHypersensitivity ReactionsMalignant NeoplasmsMetastatic Breast CancerTumor AntigensTumor-associated AntigensAutoantibody Cross-reactivityDelayed Cutaneous HypersensitivityDelayed Hypersensitivity ReactionsIntradermal Skin TestingLymph Node MetastasesMalignant Breast TumorsRegional Lymph Node MetastasisTumor Reactivity
In a group of 56 patients, 12 have shown a delayed hypersensitivity reaction (D.H.R.) to cellular extracts of their tumor. Such patients have anaplastic tumors with regional node metastases, and they tend to have significant stromal infiltrate of their tumor by mononuclear cells. Repeat skin testing with auto-logous extracts gave weaker reactions, up to 34 months after the first skin testing. Antigen stored at-20C causes a positive D.H.R. after 5 years in other patients, and cross reactivity occurred in approximately 50% of those cases tested. Shortened survival is seen in the majority of those patients who have a D.H.R. to their own tumor. This is interpreted as being due to inadequacy of this restraint of growth by the cellular defense mechanism in the face of a virulent tumor. In three patients who had an intense round cell infiltrate and a D.H.R. to the tumor, survival of 5, 5, and 5½ years, respectively, is seen.
7
The relatively favorable prognosis of medullary carcinoma of the breast
Oliver S. Moore, Frank W. Foote · Cancer · 1949 · 247 citations
Determination of cerebrospinal fluid protein with the Folin phenol reagent.
Daughaday Wh, Lowry Oh, Rosebrough Nj et al. · PubMed · 1952 · 185 citations
Inflammation, Immunity, and Hypersensitivity
Frank W. Fitch · JAMA · 1971 · 141 citations
T. H. M. Stewart · Cancer · 1969 · 78 citations
Life Sciences, Immunology, Oncology +13